{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T11:43:13Z","timestamp":1792755793513,"version":"4.5.0"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To clarify the effectiveness and safety of subcutaneous injections (SC) of methotrexate (MTX) in Japanese patients with rheumatoid arthritis using real-world data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this retrospective observational study, 82 patients with rheumatoid arthritis were administered SC MTX at our department and affiliated facilities for 24\u00a0weeks after approval in September 2022. Drug continuation rate, disease activity, clinical symptoms including adverse events, and glucocorticoid dose after SC MTX administration were retrospectively examined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The patients\u2019 background: age 59.8\u00a0years, male\/female 16\/66, disease duration 8.6\u00a0years, stage I\/II\/III\/IV 36\/32\/2\/11, DAS28-ESR 3.5, Clinical Disease Activity Index 10.4, and Simplified Disease Activity Index 11.2. The SC MTX continuation rate after 24\u00a0weeks (primary endpoint) was 86.6%. In 72 of 82 patients (87.8%), oral MTX was switched to SC MTX. Mean oral MTX dose before the switch was 10.6\u00a0mg\/week. The mean maximum dose after switching to SC was 12.0\u00a0mg\/week. Adverse events were observed in 30 patients (36.6%), with a total Common Terminology Criteria for Adverse Events grade of 2 or lower. Clinical symptoms such as nausea, liver dysfunction, and stomatitis improved in 15 (20.8%) patients. In 53 patients who switched from oral to SC MTX, the disease activity scores were improved, and the glucocorticoid dose could be reduced.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In real-world setting, switching from oral to SC MTX is useful in Japanese patients with rheumatoid arthritis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/mr\/roaf093","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T12:08:12Z","timestamp":1759925292000},"page":"190-195","source":"Crossref","is-referenced-by-count":4,"title":["The effectiveness and safety of subcutaneous methotrexate injection in Japanese patients with rheumatoid arthritis in a real-world setting"],"prefix":"10.1093","volume":"36","author":[{"given":"Yuta","family":"Shimomura","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Wakayama Medical University"},{"name":"Department of Internal Medicine, Kitade Hospital , 728-4 Takara, Yukawa, Wakayama 644-0011 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2076-1603","authenticated-orcid":false,"given":"Shigeru","family":"Iwata","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Wakayama Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Matsumiya","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Wakayama Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Wakayama Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kodai","family":"Ueno","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Wakayama Medical University"},{"name":"Department of Internal Medicine, Kainan Iryou Center , 1522-1 Hikata, Kainan, Wakayama 642-0002 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Nishikawa","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Wakayama Medical University"},{"name":"Department of Internal Medicine, Wakayama Rosai Hospital , 93-1 Kinomoto, Wakayama 640-8505,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeru","family":"Sonoda","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Wakayama Medical University"},{"name":"Department of Respiratory Medicine, NHO Wakayama Hospital , 1138 Wada, Mihama, Hidaka, Wakayama, 644-0044 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Fujii","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Wakayama Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,9]]},"reference":[{"key":"2026030510214273500_ref1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2026030510214273500_ref2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/mr\/road098","article-title":"Japan College of Rheumatology guidance for the use of methotrexate in patients with rheumatoid arthritis: secondary publication","volume":"34","author":"Kameda","year":"2023","journal-title":"Mod Rheumatol"},{"key":"2026030510214273500_ref3","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1136\/annrheumdis-2014-205228","article-title":"Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses \u226515 mg may be overcome with subcutaneous administration","volume":"73","author":"Schiff","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2026030510214273500_ref4","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1136\/annrheumdis-2014-206504","article-title":"The comparative effectiveness of oral versus subcutaneous methotrexate for the treatment of early rheumatoid arthritis","volume":"75","author":"Hazlewood","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2026030510214273500_ref5","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/art.23144","article-title":"Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial","volume":"58","author":"Braun","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2026030510214273500_ref6","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1093\/mr\/roac103","article-title":"Efficacy and tolerability of subcutaneously administered methotrexate including dose escalation in long-term treatment of rheumatoid arthritis in a Japanese population","volume":"33","author":"Tanaka","year":"2023","journal-title":"Mod Rheumatol"},{"key":"2026030510214273500_ref7","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1093\/mr\/roac017","article-title":"Drug treatment algorithm and recommendations from the 2020 update of the Japan college of rheumatology clinical practice guidelines for the management of rheumatoid arthritis-secondary publication","volume":"33","author":"Kawahito","year":"2023","journal-title":"Mod Rheumatol"},{"key":"2026030510214273500_ref8","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s12325-016-0295-8","article-title":"Methotrexate and rheumatoid arthritis: current evidence regarding subcutaneous versus oral routes of administration","volume":"33","author":"Bianchi","year":"2016","journal-title":"Adv Ther"},{"key":"2026030510214273500_ref9","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.semarthrit.2015.02.009","article-title":"Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: a retrospective analysis of real-world data from the St. Gallen cohort","volume":"45","author":"M\u00fcller","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"2026030510214273500_ref10","doi-asserted-by":"publisher","first-page":"470","DOI":"10.3109\/03009742.2014.910312","article-title":"Retrospective evaluation of continuation rates following a switch to subcutaneous methotrexate in rheumatoid arthritis patients failing to respond to or tolerate oral methotrexate: the MENTOR study","volume":"43","author":"Scott","year":"2014","journal-title":"Scand J Rheumatol"},{"key":"2026030510214273500_ref11","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1136\/annrheumdis-2016-210246","article-title":"Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial","volume":"76","author":"Atsumi","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2026030510214273500_ref12","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1093\/rheumatology\/keq216","article-title":"Red blood cell methotrexate polyglutamates emerge as a function of dosage intensity and route of administration during pulse methotrexate therapy in rheumatoid arthritis","volume":"49","author":"Dervieux","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"2026030510214273500_ref13","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1002\/acr.24334","article-title":"Safety and tolerability of subcutaneous methotrexate in routine clinical practice","volume":"73","author":"Li","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026030510214273500_ref14","doi-asserted-by":"publisher","first-page":"15116","DOI":"10.3390\/ijms232315116","article-title":"Methotrexate-induced liver injury is associated with oxidative stress, impaired mitochondrial respiration, and endoplasmic reticulum stress In vitro","volume":"23","author":"Schmidt","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026030510214273500_ref15","doi-asserted-by":"crossref","first-page":"152840","DOI":"10.1016\/j.tox.2021.152840","article-title":"Hepatotoxic potentials of methotrexate: understanding the possible toxicological molecular mechanisms","volume":"458","author":"Ezhilarasan","year":"2021","journal-title":"Toxicology"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roaf093\/64573414\/roaf093.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/36\/2\/190\/64573414\/roaf093.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/36\/2\/190\/64573414\/roaf093.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T15:21:47Z","timestamp":1772724107000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/36\/2\/190\/8279882"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,9]]},"references-count":15,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,10,9]]},"published-print":{"date-parts":[[2026,3,5]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roaf093","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2025,10,9]]}}}